Alnylam Pharmaceuticals, Inc. (ALNY) rated Mkt Outperform with price target $12 by Rodman & Renshaw
Rodman & Renshaw rated Mkt Outperform Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) on 10/14/2011. Previously Rodman & Renshaw rated Buy Alnylam Pharmaceuticals, Inc. (NASDAQ:
ALNY) on 07/10/2007., when the stock price was $22.95. Since then, Alnylam Pharmaceuticals, Inc. has gained 275.51% as of 10/23/2014's recent price of $86.18. If you would have followed the previous Rodman & Renshaw's recommendation on ALNY, you would have gained 275.51% of your investment in 2662 days.
Alnylam Pharmaceuticals, Inc.
is a biopharmaceutical company developing novel therapeutics based on RNA interference, or RNAi. The company is applying its therapeutic expertise in RNAi to address significant medical needs, many of which cannot effectively be addressed with small molecules or antibodies, the current major classes of drugs. Alnylam is building a pipeline of RNAi therapeutics; its lead program is in Phase I human clinical trials for the treatment of respiratory syncytial virus infection, which is the leading cause of hospitalization in infants in the U.S. The company's leadership position in fundamental patents, technology, and know-how relating to RNAi has enabled it to form major alliances with leading companies including Merck, Medtronic, Novartis, and Biogen Idec.
Rodman & Renshaw
is a full-service investment bank dedicated to providing investment banking services to companies that have significant recurring capital needs due to their growth and development strategies. We also provide research and sales and trading services to institutional investor clients that focus on such companies. Since 2003, Rodman has been a leading investment banking firm to the biotechnology sector, a capital intensive market segment, as well as a leader in the PIPE (private investment in public equity) and RD (registered direct placements) transaction markets.